17:41:07 EST Thu 12 Nov 2026
Enter Symbol
or Name
USA
CA



Grown Rogue International Inc. - Subordinate Voting Shares
Symbol GRIN
Shares Issued 143,421,865
Close 2026-11-11 C$ 0.47
Market Cap C$ 67,408,277
Recent Sedar+ Documents

ORIGINAL: Grown Rogue Reports Third Quarter 2026 Results

2026-11-12 16:05 ET - News Release

Grown Rogue Reports Third Quarter 2026 Results

Canada NewsWire

Steady Execution Across Existing and New Markets; 2026 and 2027 Guidance and Growth Targets Maintained

MEDFORD, Ore., Nov. 12, 2026 /CNW/ -- Grown Rogue International Inc. ("Grown Rogue," "we," "us," "our," or the "Company") (CSE: GRIN) (OTC: GRUSF), a flower-forward cannabis company combining craft values with disciplined execution, today reported its unaudited financial results for the three and nine months ended September 30, 2026.

Grown Rogue International

Results are presented in U.S. dollars and in accordance with U.S. generally accepted accounting principles ("GAAP"). Comparative periods have been recast, where applicable, in accordance with GAAP.

Obie Strickler, Chief Executive Officer, said: "For us, it always comes back to the people buying what we make. They're spending their hard-earned money and trusting us to deliver products worth coming back for. We take that responsibility seriously, and as we grow, so does our commitment to getting it consistently right. I'm incredibly proud of how our team has maintained that focus while bringing several new markets online simultaneously. We've welcomed talented new people who are working alongside our existing team, bringing fresh perspectives to our deep operational experience. This combination gives me tremendous confidence in our ability to execute on our ambitious growth plans."

Highlights
  • Revenue: Revenue of $11.0 million for the third quarter of 2026, compared with $8.5 million in the third quarter of 2025, an increase of 29% (25% excluding the Michigan wholesale excise tax reported as revenue). Growth was driven by revenue increases of 44% in New Jersey, 21% in Oregon and 19% in Michigan (5% excluding the excise tax).
  • Adjusted EBITDA: Adjusted EBITDA (non-GAAP) of $2.6 million, compared with $1.5 million in the third quarter of 2025, with an Adjusted EBITDA margin of 23.3%. See "Non-GAAP Financial Measures" and the reconciliation schedule.
  • GAAP Net Loss: Net loss was $8.9 million, compared with net income of $1.6 million in the prior-year period. The quarter included a $5.0 million loss on acquisition of Rogue EBC, LLC, following the Company's decision to enter Illinois through the existing, formerly PharmaCann-operated Dwight cultivation facility under its arrangement with SEA Craft, rather than develop the planned Waukegan facility.
  • Cash Position: Cash and cash equivalents of $16.6 million at September 30, 2026, compared with $11.5 million at June 30, 2026, with the increase related to the consolidation of Grown Rogue New York, LLC ("GRNY"), which is the Company's 51%-owned subsidiary with agreements to manage and plans to acquire the license and select assets of PharmaCann of New York LLC ("PCNY"), offset by planned capital expenditures in New Jersey and Minnesota.
  • Operating Performance: New Jersey delivered strong financial results alongside continued improvements in flower quality and yields. Oregon and Michigan increased total flower yields and reduced production costs in highly price-competitive markets.
  • New Market Milestones: Cultivation commenced at the Fridley, Minnesota facility, with the first harvest scheduled at the end of November. Affiliate SEA Craft completed its first flower sales in Illinois after quarter-end. Work has also begun to revitalize cultivation in Hamptonburgh, New York, under Grown Rogue's agreements with PCNY, with the first harvest scheduled in December.
  • Guidance: The Company is maintaining its 2026 guidance of $38–$41 million in revenue and $7–$9 million in Adjusted EBITDA, and its 2027 guidance of $55–$63 million in revenue and $14–$18 million in Adjusted EBITDA, along with its long-term growth objectives. These expectations exclude New York. Management plans to revisit these expectations to incorporate New York when reporting fourth quarter and full year 2026 results.

Management Commentary and Outlook

"New Jersey had another strong quarter, with the consistent sell-through of branded, packaged products at attractive pricing demonstrating our ability to resonate with customers, and continued progress in our quality and efficiency KPIs," said Obie Strickler. "We're excited to have plants growing in Minnesota, with our first harvest in late November, and our first branded flower already on the shelves in Illinois. Entering a market is just the beginning. The real work now begins to earn the trust and respect of customers by making sure our passion and relentless focus on quality products shine through.

"Oregon and Michigan remain foundational markets for honing our operations and developing our talent. I'm really pleased with the progress these teams are making in improving yields and bringing costs down, while building bench strength and finding better ways of working that carry across our markets. They keep raising the bar for what I think is possible in efficiency and quality."

Josh Rosen, Chief Strategy Officer, added: "Two years ago, we believed that increasing distress in some corners of the cannabis industry would create significant opportunities for companies positioned to act. Since then, we've strengthened Grown Rogue with supportive capital and additional talent, building an organization ready for greater scale. Those opportunities have now materialized, with our announced plans to enter New York the largest to date."

"Our focus remains on execution. In New York specifically, PCNY's existing infrastructure gives us a substantial foundation, and I'm pleased with how quickly our team and the local PCNY team have mobilized to restart cultivation and re-energize the dispensaries. We anticipate PCNY should be back in the wholesale market in early 2027 and we are working diligently to support the execution of the purchase agreements and regulatory approvals needed to close these transactions."

Andrew Marchington, Chief Financial Officer, said: "The $5.0 million loss on the acquisition of Rogue EBC reflects the accounting impact associated with that transaction following our decision to pursue the existing turnkey Dwight facility rather than build a new facility in Waukegan. We are in discussions to offset some of our ongoing Rogue EBC obligations."

He added: "We're expanding our finance and support teams alongside our operating footprint, particularly to manage the increased work coming from our New York efforts. The New York transaction will add complexity to our fourth quarter and year-end closing and audit process. Assuming we execute the definitive purchase agreements in the fourth quarter, we anticipate the need to consolidate PCNY's results beginning on the date of the executed purchase agreements.  PCNY's corporate parent has been liquidating assets for more than a year and we anticipate the combination of headcount attrition and liquidity constraints may impact their ability to support our back-office integration and transition priorities, including our audit, and we are proactively preparing for these challenges."

Third Quarter Operating Update

New Jersey revenue was $4.9 million and Adjusted EBITDA was $2.4 million, up 44% and 65%, respectively, from the third quarter of 2025. Compared with the second quarter of 2026, total flower yield increased to 63 grams per square foot from 61, and "A" flower yield increased to 45 grams per square foot from 41. Phase II construction continued toward approximately 16,000 square feet of total flowering canopy, with substantial completion targeted by year-end and additional capacity expected to contribute more significantly to sales in 2027.

As anticipated, Oregon and Michigan remained highly price-competitive. Compared with the second quarter, total flower yield increased to 85 grams per square foot from 76 in Oregon and to 93 from 90 in Michigan. Cost per pound declined to $284 from $326 in Oregon and to $255 from $277 in Michigan. These improvements supported operating efficiency and informed practices across the broader organization, although pricing continued to weigh on financial performance.

In Minnesota, cultivation began at our Fridley facility following approval to operate. Phase I includes approximately 8,000 square feet of flowering canopy across five constructed flower rooms, being populated sequentially. The first harvest is anticipated in late November, with harvests every two weeks thereafter and first sales expected in January 2027.

New York Transaction Update

In August 2026, Grown Rogue established its 51%-owned subsidiary, GRNY, and entered into financing, consulting, lease and funding arrangements supporting the planned acquisition of PharmaCann's New York license and most of its assets. The planned transaction includes the Hamptonburgh cultivation and manufacturing facility and four Verilife dispensaries.

Under the Goods and Services Agreement ("GSA") executed on August 20, 2026, GRNY began supporting the operating transition, including the revitalization of cultivation at Hamptonburgh. The first harvest is anticipated in December 2026. Immediate priorities include establishing consistent cultivation performance and re-energizing the existing retail business following several months of heavy promotional and product liquidation activity.

A capital partner invested $10 million for a 49% preferred equity interest in GRNY and committed an additional $5 million drawable term loan. At announcement, estimated project costs, including the acquisition, capital expenditures and working capital, were approximately $12 million. A secured funding facility of up to $9 million from GRNY to PCNY supports the transition.

Subsequent Events

The following developments occurred after September 30, 2026.

New Jersey ownership: On October 20, 2026, the Company announced completion of its second option exercise, increasing its ownership of ABCO Garden State, LLC ("ABCO") by 26% to 70% and obtaining majority board control. Regulatory approval was received on September 16, 2026. The approximately $743,000 consideration had been advanced in 2023.

Illinois first sales: On October 22, 2026, the Company announced that affiliate SEA Craft LLC ("SEA Craft") had completed its first deliveries of Grown Rogue products to select Illinois dispensaries that week. Initial flowering canopy comprises approximately 5,000 square feet, with initial expansion work toward approximately 10,000 square feet underway. The pace of additional capacity will be informed by operating performance and market demand, subject to applicable regulatory requirements.

Operating KPIs by Market

Metric

Q3 2026

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Oregon*






Total Flower Harvested (lbs)

4,255

3,594

3,277

2,980

3,547

Flower Cost Per Pound Produced

$284

$326

$342

$379

$294

Total Flower Yield (g/sf)¹

85

76

69

68

73

"A" Flower Yield (g/sf)¹

52

53

50

42

49

$ Bulk Flower ASP²

$577

$592

$480

$466

$499

$ Packaged Flower ASP²

—

—

—

—

—

Portion of Revenue for Packaged Products

12 %

10 %

11 %

9 %

15 %

Michigan






Total Flower Harvested (lbs)

4,319

4,259

3,746

3,960

3,518

Flower Cost Per Pound Produced

$255

$277

$304

$287

$312

Total Flower Yield (g/sf)¹

93

90

84

82

77

"A" Flower Yield (g/sf)¹

52

56

52

49

46

$ Bulk Flower ASP²˒³

$660

$615

$599

$692

$775

$ Packaged Flower ASP²˒³

$827

$861

$889

$957

$900

Portion of Revenue for Packaged Products

35 %

27 %

20 %

24 %

17 %

New Jersey






Total Flower Harvested (lbs)

2,025

1,910

1,700

1,678

1,306

Flower Cost Per Pound Produced

$685

$670

$652

$582

$770

Total Flower Yield (g/sf)¹

63

61

63

64

59

"A" Flower Yield (g/sf)¹

45

41

37

37

38

$ Bulk Flower ASP²

n.m.⁴

n.m.⁴

n.m.⁴

$1,193

$1,032

$ Packaged Flower ASP²˒⁵

$2,021

$2,077

$2,149

$2,305

$2,365

Portion of Revenue for Packaged Products

99 %

100 %

97 %

95 %

92 %


* Includes only indoor operations.


1 Total flower harvested and yield metrics reflect whole flower and exclude material used in ground flower and shake products. g/sf = grams of whole flower harvested per square foot of growing space. Q3 2026 harvested weights include estimates for three late-September Michigan harvests totaling 705 lbs and one Oregon harvest totaling 112 lbs. These Q3 yield values are treated as final; historically, differences between estimated and actual weights have been immaterial.


2 ASP = average selling price per pound. Oregon packaged-product revenue consists of pre-rolls, which are included in the packaged-products revenue percentage but excluded from packaged-flower ASP; accordingly, no Oregon packaged-flower ASP is presented.


3 Michigan ASP excludes amounts related to the Michigan wholesale excise tax included in reported revenue in 2026.


4 Not meaningful.


5 New Jersey packaged-flower ASP for all periods presented has been recast to exclude ground flower products, a category consisting predominantly of shake.

Selected Quarterly Financial Results (Unaudited)

Metric

Q3 2026

Q3 2025

YoY change

Q2 2026

Revenue (GAAP)

$11.0 million

$8.5 million

+29 %

$11.3 million

Gross Profit

$5.5 million

$3.7 million

+50 %

$5.4 million

Gross Margin

49.8 %

43.0 %

+6.8 pp

47.6 %

GAAP Net Income (Loss)

($8.9) million

$1.6 million

n.m.

($1.5) million

EBITDA (Non-GAAP)

($4.5) million

$3.5 million

n.m.

$0.6 million

Adjusted EBITDA (Non-GAAP)

$2.6 million

$1.5 million

+70 %

$2.1 million

Adjusted EBITDA Margin

23.3 %

17.7 %

+5.6 pp

18.2 %

Cash and Cash Equivalents

$16.6 million
as of Sep. 30, 2026

$13.6 million
as of Sep. 30, 2025

+22 %

$11.5 million
as of Jun. 30, 2026


n.m. = not meaningful. pp = percentage points. EBITDA and Adjusted EBITDA are non-GAAP financial measures. Prior-period EBITDA has been recast to conform to the current presentation; Adjusted EBITDA is unchanged. See "Non-GAAP Financial Measures" and the reconciliation schedule. Percentage changes are calculated from unrounded figures.

Selected Quarterly Financial Results by Segment (Unaudited)

Metric

Q3 2026

Q3 2025

YoY change

Q2 2026

Oregon





Revenue (GAAP)

$3.1 million

$2.6 million

+21 %

$3.5 million

Adjusted EBITDA

$0.3 million

$0.2 million

+121 %

$0.7 million

Adjusted EBITDA Margin

11.0 %

6.0 %

+5.0 pp

20.8 %

Michigan*





Revenue (GAAP)

$3.0 million

$2.5 million

+19 %

$3.4 million

Adjusted EBITDA

$0.8 million

$0.8 million

-10 %

$0.7 million

Adjusted EBITDA Margin

25.1 %

33.5 %

-8.3 pp

20.0 %

New Jersey





Revenue (GAAP)

$4.9 million

$3.4 million

+44 %

$4.4 million

Adjusted EBITDA

$2.4 million

$1.4 million

+65 %

$1.8 million

Adjusted EBITDA Margin

48.6 %

42.3 %

+6.3 pp

42.2 %

Corporate





Adjusted EBITDA

($0.9) million

($0.9) million

3% lower expense

($1.2) million

Consolidated





Revenue (GAAP)

$11.0 million

$8.5 million

+29 %

$11.3 million

Adjusted EBITDA

$2.6 million

$1.5 million

+70 %

$2.1 million

Adjusted EBITDA Margin

23.3 %

17.7 %

+5.6 pp

18.2 %


* Michigan revenue includes $0.35 million of wholesale excise tax in Q3 2026. Adjusted EBITDA margins use reported revenue. Percentage changes are calculated from unrounded figures.

Guidance and Long Term Growth Objectives

The Company is maintaining its previously announced 2026 and 2027 revenue and Adjusted EBITDA guidance and long-term growth objectives, with a reminder that the fourth quarter is typically seasonally slower than the third quarter. These expectations exclude New York. Management plans to revisit the outlook to incorporate New York when reporting fourth quarter and full year 2026 results.

Measure

2026 guidance

2027 guidance

Revenue

$38–$41 million

$55–$63 million

Adjusted EBITDA non-GAAP

$7–$9 million

$14–$18 million

The Company's three-to-five-year objectives, using 2027 as the base year, remain 25% annual compounded revenue growth, 35% annual compounded Adjusted EBITDA growth and return on incremental invested capital ("ROIIC") greater than 75%.

Grown Rogue's growth approach combines selective new builds, the revitalization of existing facilities and focused expansion of flower-forward products. Management evaluates opportunities using normalized market pricing and disciplined capital-allocation criteria.

Guidance Assumptions

The outlook continues to reflect Illinois sales beginning in Q4 2026, Minnesota first revenue in Q1 2027 and a greater contribution from New Jersey's Phase II expansion in 2027. Adjusted EBITDA guidance excludes pre-revenue startup expenses associated with new-market expansion, estimated at $1.5 million to $2.0 million in each of Illinois and Minnesota for 2026.

The previously disclosed 2027 framework assumes wholesale price normalization of approximately 10% in New Jersey and 5% in Illinois, no change in the Oregon and Michigan pricing environment, and Minnesota "A" flower wholesale pricing above $2,500 per pound. It also assumes continued capacity expansion in Illinois and Minnesota.

Flowering Capacity by Market

Square feet of flowering bench canopy as of September 30, 2026. Nameplate represents potential capacity, not a commitment to develop that capacity.

State

Online canopy
(sq. ft.)

Under development
(sq. ft.)

Nameplate capacity
(sq. ft.)

Notes

Oregon (indoor only)

14,752

N/A

14,752

Approximately 30,000 sq. ft. of indoor facility space at the Airport facility. Eight dedicated flower rooms and nearly four harvests per month at the Rossanley facility.

Michigan

14,550

N/A

14,550

Facility currently operates approximately 50,000 sq. ft., including fourteen flowering rooms and related support space.

New Jersey

10,000

6,000

16,000

Expansion underway through 2026, with total flowering canopy anticipated to increase to approximately 16,000 sq. ft.

Minnesota

8,000

0

30,000

Phase I includes approximately 8,000 sq. ft. of flowering canopy, with products expected to be available for sale in early 2027.

Illinois

5,000

5,000

14,000

Approximately 66,000 sq. ft. leased facility, including a 23,000 sq. ft. greenhouse, with 5,000 sq. ft. of indoor flowering canopy online and an additional 5,000 sq. ft. under development. Expandable to approximately 14,000 sq. ft., subject to regulatory approval.

Totals

52,302

11,000

89,302


Conference Call and Webcast Information

Grown Rogue will host a conference call and webcast on Thursday, November 12, 2026, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss its third quarter 2026 results and provide a corporate update. CEO Obie Strickler and members of the management team will host the call, followed by a question-and-answer period.

Detail

Information

Date

Thursday, November 12, 2026

Time

5:00 p.m. ET / 2:00 p.m. PT

Webcast registration

https://app.webinar.net/l6X5PNWbK9y

Dial-in

1-800-836-8184 toll-free in North America

A telephone replay will be available until November 19, 2026, by dialing (+1) 888-660-6345 and entering replay code 95406#. A transcript, the earnings release, financial filings and related investor materials will be available at ir.grownrogue.com.

About Grown Rogue

Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a flower-forward cannabis company rooted in Oregon's Rogue Valley, a region with a deep cannabis heritage where its founders began growing more than 20 years ago. Built on a love of the plant, the Company produces flavorful craft-quality flower and the products made from it.

Its approach brings together a distinct and constantly expanding library of genetics, developed in house and sourced from like-minded breeders; a passionate, experienced team of growers; and the discipline to keep learning from every harvest. The goal is to consistently deliver quality that retailers and budtenders can stand behind and consumers come back for.

Grown Rogue believes trust is earned one harvest at a time and is currently serving customers in Oregon, Michigan, New Jersey and Illinois, with launches planned in Minnesota and New York.

For more information about Grown Rogue, please visit www.grownrogue.com. Investor materials are available at ir.grownrogue.com. The contents of the Company's websites are not incorporated by reference into this press release or into any report or document filed or furnished by the Company with the SEC or Canadian securities regulators, and references to the websites are intended to be inactive textual references only.

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)
Unaudited • U.S. dollars, except share and per-share amounts • Three and nine months ended September 30.


Three months
2026

Three months
2025

Nine months
2026

Nine months
2025

Revenues





Product sales

11,019,038

8,514,268

31,448,533

23,674,438

Total revenue

11,019,038

8,514,268

31,448,533

23,674,438

Cost of goods sold





Cost of finished cannabis inventory sold

(5,536,034)

(4,855,244)

(16,637,918)

(13,097,182)

Total cost of goods sold

(5,536,034)

(4,855,244)

(16,637,918)

(13,097,182)

Gross profit

5,483,004

3,659,024

14,810,615

10,577,256

Operating expenses





Depreciation

89,213

110,693

246,025

323,604

General and administrative

5,332,245

2,964,469

13,262,652

8,175,095

Share-based compensation

328,455

314,951

632,536

2,087,686

Total operating expenses

5,749,913

3,390,113

14,141,213

10,586,385

Income (loss) from operations

(266,909)

268,911

669,402

(9,129)

Other income (expense)





Interest and accretion expense

(532,984)

(410,925)

(1,512,204)

(1,101,649)

Other income (expense)

96,996

119,703

146,136

742,772

Interest income

46,264

36,736

192,807

109,010

Unrealized gain (loss) on derivative liability

131,671

(24,242)

280,054

(51,896)

Realized gain on derivative liability

—

—

—

5,859,744

Unrealized loss on warrant asset

(105,528)

2,162,087

(2,853,195)

821,433

Unrealized gain on warrant liability

(64,444)

—

369,103

—

Loss on acquisition of Rogue EBC

(5,030,332)

—

(5,030,332)

—

Loss on equity investment in associate

(8,180)

(75,733)

(301,430)

(344,153)

Total other income (expense), net

(5,466,537)

1,807,626

(8,709,061)

6,035,261

Income (loss) before income tax expense

(5,733,446)

2,076,537

(8,039,659)

6,026,132

Income tax expense

(3,154,693)

(511,381)

(4,542,895)

(2,062,728)

Net income (loss)

(8,888,139)

1,565,156

(12,582,554)

3,963,404

Other comprehensive income (loss)





Currency translation adjustment

—

2,736

—

4,021

Total comprehensive income (loss)

(8,888,139)

1,567,892

(12,582,554)

3,967,425

Basic income (loss) per share

(0.04)

0.01

(0.05)

0.02

Basic weighted average number of subordinate voting common shares outstanding

249,938,980

249,707,811

249,930,921

241,335,995

Diluted income (loss) per share

(0.04)

0.01

(0.05)

0.02

Diluted weighted average number of subordinate voting common shares outstanding

249,938,980

253,827,006

249,930,921

247,687,866

Net income (loss) for the period attributable to:





Shareholders

(9,078,320)

668,500

(13,473,373)

2,767,257

Non-controlling interest

1,279,574

896,656

1,980,212

1,196,147

Redeemable non-controlling interest

(1,089,393)

—

(1,089,393)

—

Net income (loss)

(8,888,139)

1,565,156

(12,582,554)

3,963,404

Total comprehensive income (loss) for the period attributable to:





Shareholders

(9,078,320)

671,236

(13,473,373)

2,771,278

Non-controlling interest

1,279,574

896,656

1,980,212

1,196,147

Redeemable non-controlling interest

(1,089,393)

—

(1,089,393)

—

Total comprehensive income (loss)

(8,888,139)

1,567,892

(12,582,554)

3,967,425

Condensed Consolidated Balance Sheets
Unaudited • U.S. dollars


September 30, 2026

December 31, 2025

ASSETS



Current



Cash

16,602,268

11,371,834

Accounts receivable

3,894,962

2,908,270

Inventory

7,338,731

7,081,295

Prepaid expenses

2,489,611

563,912

Derivative asset

143,013

—

Current portion of notes receivable

272,361

253,403

Total current assets

30,740,946

22,178,714

Other long term assets

500,000

300,000

Warrants asset

2,250,077

5,103,272

Other investments

—

1,358,860

Notes receivable

3,777,187

1,683,757

Lease receivable

94,022

94,022

Property and equipment

20,999,582

14,055,552

Right of use assets - operating

35,662,493

13,414,406

Right of use assets - finance

2,639,306

—

Deferred tax asset

1,744,522

1,522,760

Intangible assets and goodwill

3,025,193

3,025,193

Total assets

101,433,328

62,736,536

LIABILITIES



Current



Accounts payable and accrued liabilities

4,863,725

1,262,519

Current portion of operating lease liabilities

2,824,083

844,421

Current portion of finance lease liabilities

297,188

152,705

Current portion of long-term debt

3,011,112

2,576,228

Current portion of business acquisition consideration payable

1,468,315

455,844

Derivative liability

—

137,041

Current portion of warrant liability

1,170,562

—

Income tax payable

725,453

296,018

Total current liabilities

14,360,438

5,724,776

Operating lease liabilities

39,371,232

13,010,805

Finance lease liabilities

2,447,722

67,782

Long-term debt

8,757,646

10,019,301

Business acquisition consideration payable

1,439,443

1,611,637

Other non-current liabilities

12,094,117

8,383,888

Total liabilities

78,470,598

38,818,189

Redeemable non-controlling interest

8,910,607

—

SHAREHOLDERS' EQUITY (DEFICIENCY)



Capital stock

61,841,785

62,589,075

Multiple voting common shares

—

—

Accumulated other comprehensive loss

(121,906)

(121,906)

Accumulated Deficit

(55,037,328)

(41,563,955)

Equity attributable to shareholders of the Company

6,682,551

20,903,214

Non-controlling interests

7,369,572

3,015,133

Total shareholders' equity

14,052,123

23,918,347

Total liabilities and shareholders' equity

101,433,328

62,736,536

Condensed Consolidated Statements of Cash Flows
Unaudited • U.S. dollars


Nine months ended
September 30, 2026

Nine months ended
September 30, 2025

Operating activities:



Net income (loss)

(12,582,554)

3,963,404

Adjustments for non-cash items in net income (loss):



Depreciation of property and equipment

246,025

323,604

Depreciation of property and equipment included in costs of finished cannabis inventory sold

2,106,425

1,443,153

Lease costs included in costs of finished cannabis inventory sold

954,016

119,690

Share-based compensation

632,536

2,087,686

Interest and accretion expense

170,305

433,316

Other income

—

(61,379)

Interest income

(127,969)

(109,010)

Unrealized (gain) loss on derivative liability

(280,054)

51,896

Realized (gain) loss on derivative liability

—

(5,859,744)

Unrealized loss on warrant asset

2,853,195

(821,433)

Unrealized gain on warrant liability

(369,103)

—

Loss on acquisition of Rogue EBC

5,030,332

—

Loss on equity investment in associate

301,430

344,153

Deferred income taxes

(221,762)

(607,238)

Lease incentives received (tenant improvement allowance)

2,745,833

—

Changes in non-cash working capital

5,981,285

(1,323,158)

Net cash provided by (used in) operating activities

7,439,940

(15,060)

Investing activities:



Purchase of property and equipment

(9,335,612)

(1,072,054)

Payments of business acquisition consideration payable

(115,949)

(139,944)

Advance of notes receivable

(1,984,419)

—

Advance of security deposit

(200,000)

—

Cash acquired on purchase of remaining Rogue EBC, LLC equity interest

35,879

—

Advance on purchase of remaining Rogue EBC, LLC equity interest

(465,000)

(1,127,781)

Deposit paid toward proposed acquisition

(1,515,580)

—

Net cash used in investing activities

(13,580,681)

(2,339,779)

Financing activities



Proceeds from issuance of GRNY preferred units

10,000,000

—

Sale of non-controlling interest in GRMA, net of issuance costs

2,985,000

—

Dividends to non-controlling interests from subsidiaries

(610,773)

(115,000)

Proceeds from long-term debt

500,000

12,630,346

Debt issuance costs

—

(627,189)

Repayment of long-term debt

(1,507,273)

(1,273,742)

Repayment of finance lease

(17,618)

(2,879)

Proceeds from exercise of stock options

21,839

402,844

Net cash provided by financing activities

11,371,175

11,014,380

Effect of exchange rate on changes in cash

—

4,021

Change in cash and cash equivalents

5,230,434

8,663,562

Cash and cash equivalents, beginning of period

11,371,834

4,917,708

Cash and cash equivalents, ending of period

16,602,268

13,581,270

Cash paid during the period for:



Cash income tax paid

287,680

645,055

Cash interest paid

1,341,899

668,333

Cash interest earned

64,838

—

Supplemental cash flow information



Fair value of SV Shares issued to settle convertible debentures

—

7,422,809

Reclassification of warrants to warrant liability from equity

1,539,665

—

Fair value of deferred commitment costs

138,000

—

Transfer of long term debt to operating lease liability

—

—

Property, plant and equipment acquired through operating lease liability

—

—

Property, plant and equipment acquired through finance lease liability

—

337,337

Right-of-use assets - operating resulting from operating lease liabilities

23,569,262

—

Right-of-use assets - finance resulting from finance lease liabilities

2,542,040

—

Right-of-use assets - finance resulting from transfer from property, plant and equipment

227,131

—

EBITDA and Adjusted EBITDA Reconciliation (Unaudited)
U.S. dollars; three and nine months ended September 30.


Three months
2026

Three months
2025

Nine months
2026

Nine months
2025

Net income (loss)

(8,888,139)

1,565,156

(12,582,554)

3,963,404

Add back amortization of property and equipment included in cost of sales

659,253

895,472

2,236,290

1,987,906

Add back interest and accretion expense

532,984

410,925

1,512,204

1,101,649

Add back amortization of property and equipment

89,213

110,693

246,025

323,604

Add back income tax expense

3,154,693

511,381

4,542,895

2,062,728

EBITDA

(4,451,996)

3,493,627

(4,045,140)

9,439,291

Add back share-based compensation

328,455

314,951

632,536

2,087,686

Deduct gain on derivative liability

(131,671)

24,242

(280,054)

(5,807,848)

Deduct interest and other income (expense)

(143,260)

(156,439)

(338,943)

(851,782)

Add back changes in FV on warrants asset and liability

169,972

(2,162,087)

2,484,092

(821,433)

Add back loss on acquisition of Rogue EBC

5,030,332

—

5,030,332

—

Add back loss on equity investment in associate

8,180

75,733

301,430

344,153

Deduct GAAP bad debt conversion adjustment

—

(79,000)

—

(237,000)

Add back Golden Harvests acquisition costs

—

—

—

60,000

Add back pre-operational startup costs

1,761,194

—

2,408,356

—

Adjusted EBITDA

2,571,206

1,511,027

6,192,609

4,213,067


Pre-operational startup costs for the nine months ended September 30, 2026 totaled $2,408,356, comprising Gopher Gardens ($1,333,276), Grown Rogue New York ($1,019,393), Rogue EBC ($54,982) and corporate costs related to Nile NJ ($705).

Cautionary Note Regarding Forward Looking Statements

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking statements"). These include statements regarding the Company's financial guidance and long-term growth and return objectives, including their exclusion of New York and the planned fourth quarter review; underlying pricing, margin, overhead and startup-cost assumptions; construction, commissioning, flowering canopy, production, harvest, sales and financial contributions in New Jersey, Illinois and Minnesota; the planned acquisition of PCNY, execution of definitive purchase agreements, regulatory submissions and approvals, closing conditions and timing; interim management, cultivation restart and retail operations in New York; the availability, terms and deployment of project financing; expected operating improvements, cash flow and capital requirements; product launches; funding of planned expansion; and future operating and financial performance.

Forward-looking statements are often identified by words or phrases such as "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect," "target," "guidance," "outlook," "forecast," "objective" and similar expressions, including their negative forms. The absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are based on management's current expectations, estimates, assumptions and projections as of the date of this release. These assumptions include, without limitation, assumptions regarding market conditions, wholesale pricing, consumer and retailer demand, competitive conditions, construction and commissioning timelines, the availability and cost of labour, materials and equipment, regulatory approvals and continued compliance with applicable licensing requirements, cultivation yields and product quality, the timing of new product and market launches, operating costs, access to capital and the Company's ability to fund its planned operations and expansion activities. With respect to New York, assumptions also include continuation of interim operating and lease arrangements, execution and performance of transaction agreements, receipt of required OCM approvals, availability of committed and additional capital when required, successful staffing and production ramp, and demand sufficient to support the operating plan.

Although the Company believes these expectations and assumptions are reasonable, forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. These risks and uncertainties include, without limitation: changes in general economic, business, political and financial-market conditions; changes in cannabis laws, regulations or enforcement policies; the timing or availability of required regulatory approvals; the continued illegality of cannabis under United States federal law; declines or volatility in wholesale cannabis pricing and demand; increased competition; variations in cultivation yields, product quality and production costs; construction, commissioning or ramp-up delays and cost overruns; the availability of labour, equipment and supplies; the Company's ability to generate sufficient cash flow or obtain financing on acceptable terms; and the other risks described in the Company's public disclosure documents filed through SEDAR+ and EDGAR. Additional risks include failure to complete the proposed PCNY acquisition, changes in transaction terms, interruptions during the transition, inability to realize projected cost savings or cash-flow improvements, limits on financing availability, financing costs and potential dilution, and adverse tax treatment, including continued application of Section 280E.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as required by applicable law. Future-oriented financial information and financial outlooks contained in this release are provided for the purpose of describing management's current expectations and may not be appropriate for other purposes.

The Company is indirectly involved, through its operating subsidiaries, in the cultivation, manufacture, possession, use, sale and distribution of cannabis in the adult-use cannabis marketplace in the United States. Although these activities are permitted under applicable state laws in the jurisdictions in which the Company operates, cannabis remains illegal under United States federal law.

Non GAAP Financial Measures

This press release presents certain financial measures that are not calculated in accordance with United States generally accepted accounting principles ("GAAP"), including EBITDA, Adjusted EBITDA, Adjusted EBITDA margin and return on incremental invested capital ("ROIIC"). These non-GAAP financial measures do not have standardized meanings prescribed by GAAP and may not be comparable with similarly titled measures presented by other companies.

Management uses these non-GAAP financial measures as supplemental tools to evaluate the Company's underlying operating performance, compare results between periods and markets, and assess capital-allocation decisions. These measures should not be considered in isolation or as a substitute for, or superior to, financial measures prepared in accordance with GAAP.

EBITDA is defined as net income (loss) before interest and accretion expense, income tax expense, and depreciation and amortization, including amortization in cost of sales. Adjusted EBITDA further adjusts EBITDA for share-based compensation, derivative gains and losses, interest and other income (expense), changes in the fair value of warrant assets and liabilities, the loss on acquisition of Rogue EBC, losses on equity investments in associates, the GAAP bad debt conversion adjustment, Golden Harvests acquisition costs and pre-operational startup costs, as applicable and as presented in the reconciliation schedule.

Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by the corresponding revenue measure. ROIIC is defined as the change in operating profit divided by the change in invested capital over the relevant measurement period.

Reconciliations of historical non-GAAP financial measures to the most directly comparable GAAP measures are included in the accompanying schedules.

SOURCE Grown Rogue International Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2026/12/c7292.html

Contact:

General Inquiries and Investor Contact: Josh Rosen, Chief Strategy Officer, joshrosen@grownrogue.com; Investor Relations: invest@grownrogue.com, (458) 226-2662

© 2026 Canjex Publishing Ltd. All rights reserved.